🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Advanced Multi-omics and -System Approaches to Identify Novel Biomarkers for SMA

Recruitingn/aAges any - anyAllIstituto Giannina Gaslini
NCT07883655 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by mutations in the SMN1 gene, leading to motor neuron degeneration and progressive muscle atrophy. Despite recent advances in therapeutic options, the clinical management of SMA remains challenging due to the heterogeneity of disease progression and variability in treatment response. This study aims to identify and validate novel biomarkers to improve the diagnosis, prognosis, and therapeutic monitoring of patients with SMA through a multi-omics and translational research approach.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Genetically confirmed diagnosis of SMA, with homozygous deletion or mutation of the SMN1 gene, for symptomatic patients. * Diagnosis of SMA through newborn screening, with genetic confirmation, for newborns. * Ability of parents/legal guardians to provide informed consent for minor patients. * Willingness to undergo the study procedures, including blood sampling and collection of biological specimens. Exclusion Criteria: * Presence of other neuromuscular or neurological diseases that could influence the clinical phenotype and biomarker profile. * Participation in other clinical trials involving investigational medicinal products for SMA within the 6 months prior to enrolment. * Presence of medical or psychological conditions that could compromise patient compliance or study safety. * Refusal to participate in the study or to provide informed consent.
💊

What it tests

  • Not listed
📍

Where

3 sites
IRCCS Istituto Giannina Gaslini
Genova, Italy
Fondazione Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
Istituto di Bioscienze e Biorisorse IBBR
Naples, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy